Background: Reported penicillin allergy rarely reflects penicillin intolerance. Failure to address inpatient penicillin allergies results in more broad-spectrum antibiotic use, treatment failures, and adverse drug events. Objective: We aimed to determine the optimal approach to penicillin allergies among medical inpatients. Methods: We evaluated internal medicine inpatients reporting penicillin allergy in 3 periods: (1) standard of care (SOC), (2) penicillin skin testing (ST), and (3) computerized guideline application with decision support (APP). The primary outcome was use of a penicillin or cephalosporin, comparing interventions to SOC using multivariable logistic regression. Results: There were 625 patients: SOC, 148; ST, 278; and APP, 199. Of 278 ST patients, 179 (64%) were skin test eligible; 43 (24%) received testing and none were allergic. In the APP period, there were 292 unique Web site views; 112 users (38%) completed clinical decision support. Although ST period patients did not have increased odds of penicillin or cephalosporin use overall (adjusted odds ratio [aOR] 1.3; 95% CI, 0.8-2.0), we observed significant increased odds of penicillin or cephalosporin use overall in the APP period (aOR, 1.8; 95% CI, 1.1-2.9) and in a perprotocol analysis of the skin tested subset (aOR, 5.7; 95% CI, 2.6-12.5). Conclusions: Both APP and ST-when completed-increased the use of penicillin and cephalosporin antibiotics among inpatients reporting penicillin allergy. While the skin tested
Penicillin allergy is reported in up to 15% of inpatients and is associated with increased use of alternative antibiotics, including vancomycin, clindamycin, aminoglycosides, and aztreonam. [1] [2] [3] [4] Compared with beta-lactam antibiotics, these drugs are less effective in some clinical circumstances, [5] [6] [7] [8] more toxic, 4,9 more costly, 10, 11 and generally cover a broader antimicrobial spectrum. When a beta-lactam antibiotic is the preferred inpatient antibiotic, but not administered because of alleged allergy, patients experience more treatment failures and adverse events. 4, 8 Patients reporting penicillin allergy have increased odds of antibioticresistant organisms, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
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Despite a reported penicillin allergy, more than 95% of patients evaluated for such allergy are found penicillin and cephalosporin tolerant. 10, [12] [13] [14] [15] [16] Therefore, active attention to clarifying old and inaccurate penicillin allergies is supported by various US guidelines and agencies as an important feature of antimicrobial stewardship. [17] [18] [19] [20] Because the optimal approach to the evaluation and management of inpatient penicillin allergy is unknown, yet impacts a substantial number of patients per year, we implemented and assessed 2 health care delivery system innovations to improve antibiotic choice among medical inpatients reporting a history of penicillin allergy.
METHODS

Design overview
We conducted a quasi-experimental study evaluating prospectively identified cohorts of internal medicine inpatients at the Brigham and Women's Hospital (BWH). We sequentially evaluated 3 strategies: (1) BWH standard of care (SOC); (2) history-appropriate penicillin skin testing (ST), a process-based innovation; and (3) a computerized guideline application with clinical decision support (APP), a technology-based innovation. We compared antibiotic use in the intervention periods to the SOC period. This study was approved by the Partners Human Research Committee.
Study population
A daily electronic tracker identified medical inpatients with a history of penicillin allergy prescribed 1 or more doses of any antimicrobial in all periods (Fig 1) . Patient readmissions and patients not meriting treatment of a presumed infection were excluded. The latter exclusion comprised patients who did not receive therapeutic antibiotics in the first 7 days of hospitalization, and those who received less than 48 hours of antibiotic therapy, accounting for both discharge antibiotics and amended dosing frequency associated with renal dosing. 21 Study periods BWH standard of care. SOC was the comparison period when no active intervention was performed. SOC patient data were collected from June 9, 2014, through November 5, 2014. As an academic, tertiary care facility, BWH has an antibiotic stewardship program that restricts some broad-spectrum and costly antibiotics (eg, linezolid and daptomycin). BWH also has a drug allergy program with inpatient Allergy/Immunology consultation and 24-hour on-call services. During SOC, all skin testing and test dose challenge 22 procedures were performed only when referred by the primary team and deemed appropriate after Allergy/Immunology consultation (see this article's Standard procedure for skin testing and test doses in all periods section and Fig E1, A, in the Online Repository at www. jacionline.org).
Penicillin skin testing. The ST period began November 12, 2014 , and continued through June 30, 2015 . During the ST period, all tracker-identified patients were screened by the care redesign team for skin test eligibility. Patients ineligible for skin testing included patients with penicillin intolerances (eg, gastrointestinal upset), patients taking medications that interfered with skin testing (eg, antihistamines), and patients with multiple beta-lactam allergies, penicillin anaphylaxis in the last 5 years, or a type II to IV hypersensitivity reaction 23 to penicillin. Skin testing was routinely intended for all skin test eligible patients, but required permission from the primary team, coordination of skin testing using a moonlighting pool of allergy trainees and nurses, and patient consent (see this article's Standard procedure for skin testing and test doses in all periods section and Fig E1, B) . Patients with both negative skin testing and tolerance of an oral amoxicillin test dose were deemed not allergic. The primary medical team and the patients were updated regarding changes in allergy status.
Computerized guideline application with clinical decision support. After a 5-month study break due to a hospitalwide electronic health record conversion, 24 the APP period ran from November 20, 2015, through June 13, 2016 (Fig E1, C) . A clinical pathway that guided beta-lactam antibiotic use in patients with listed penicillin allergy was previously developed, implemented, and assessed at an academic hospital affiliate (see this article's Evidence supporting the structure of the clinical pathway/guideline section in the Online Repository at www.jacionline. org). 5, [25] [26] [27] The guideline empowered inpatient providers to group allergic reactions into hypersensitivity type, then recommended if and how specific beta-lactam antibiotics be used (ie, very low risk, full doses; low risk, test doses; medium to high risk, Allergy/Immunology consultation; serious type II-IV hypersensitivity reactions, avoidance).
The previously studied pathway was adapted into a computerized guideline, 28 ,29 a mobile-friendly Web site with optional clinical decision support, functionally similar to a smartphone application (see this article's Development and testing of computerized guideline/app section in the Online Repository at www.jacionline.org). Because of the coincident electronic health record conversion at the BWH, the computerized guideline was not integrated into the electronic health record, but remained a distinct clinical workflow. The guideline was accessible at any BWH desktop computer or mobile device on the secure intranet. Providers could access the pathway figures directly from the Web site and/or login to use clinical decision support. After decision support computed the patient's likely allergic reaction type, it stratified the reaction into a risk category and displayed recommendations for further action (see Fig E2 in this article's Online Repository at www. jacionline.org). The Web site housed additional educational information and provider videos.
Data collection
All patient data were collected from the electronic health record, with duplicative entry, initially by research assistants (N.P. and A.E.N.), followed by internal medicine housestaff. Data were entered and maintained using Research Electronic Data Capture hosted at Partners HealthCare. 30 
Demographic characteristics
Collected patient data included age, sex, race, admission date, discharge date, admission diagnosis, allergy history, intensive care unit stay and duration time, Infectious Diseases consultation, Allergy/Immunology consultation, history of colonization or infection with methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus, renal disease, and overall length of stay. Two board-certified internists and allergists/immunologists (K.G.B. and P.G.W.) determined which admission diagnoses were related to an infection as well as which penicillin allergies were intolerances.
Intervention uptake
In the ST period, we determined the frequency with which eligible patients completed skin testing. In the APP period, we tracked usage through reports from Google Analytics Solutions (Web site views) and clinical decision support responses.
Outcomes
The primary outcome was use of formulary unrestricted penicillins or cephalosporins (see Table E1 in this article's Online Repository at www.jacionline.org). Penicillin and cephalosporin use was identified through inpatient antibiotic administrations. Secondary outcomes included the proportion of patients discharged on a penicillin or cephalosporin antibiotic, inpatient use of alternative antibiotics, and resultant adverse drug reactions.
Penicillins and cephalosporins on BWH formulary were included; cephalosporins were grouped by generation for analysis. Because of the intent to improve antibiotic choice, we excluded penicillins and cephalosporins historically restricted by BWH's antibiotic stewardship program, including piperacillin-tazobactam, ceftaroline, ceftolozane-tazobactam, and ceftazidime-avibactam. Alternative antibiotics included drugs that are potentially more toxic, less effective, more costly, and/or more broad-spectrum: vancomycin, clindamycin, daptomycin, linezolid, carbapenems, aztreonam, and aminoglycosides.
Balance measure
We analyzed macrolide antibiotic utilization as a balance measure, given its use would not be expected to change as a result of interventions related to penicillin allergy evaluation.
Statistical analysis
Study period duration and sample size were estimated in advance (see this article's Determination of innovation period length and statistical power section in the Online Repository at www.jacionline.org). Pairwise study group comparisons were specified a priori. Although the primary analysis between periods was an intention-to-treat analysis, we performed an additional secondary (per-protocol) analysis for the ST period (ST-PP) to estimate the potential impact of this strategy if it were fully implemented. Demographic data were reported as medians with quartiles or as frequencies with percentages. Fisher exact tests were used to compare study groups for binary variables, and Wilcoxon rank sum tests were used for continuous variables. Racial differences among study groups were tested using the Freeman-Halton test. Logistic regression was used to test group differences, with unadjusted and adjusted odds ratios (ORs) and 95% CIs presented. Selection of variables to include in multivariable models involved previous knowledge of association with outcome, and imbalance across the study duration. Nominal P values were reported in this context of 3 a priori nonindependent pairwise group comparisons, considering 5% 2-sided alpha. Statistical analyses were conducted using SAS 9.4 (SAS Institute, Inc, Cary, NC).
RESULTS
Cohort characteristics
Of 1000 medicine inpatients with a reported penicillin allergy prescribed 1 or more antibiotic dose, there were 780 unique patients and 625 unique patients admitted with a presumed infection across 3 periods: SOC 148, ST 278, and APP 199 (Fig 1) .
Patients' characteristics were largely balanced across periods, with a few exceptions (Table I) . Compared with the SOC period, there were fewer females in the subset of patients skin tested (ie, ST-PP analysis), more patients with an admission diagnosis of infection in the ST and APP periods, more frequent Allergy/Immunology consultation in the ST period and in the ST-PP analysis, more frequent methicillin-resistant Staphylococcus aureus colonization in the ST and APP periods, and more reported cephalosporin allergies in the ST and APP periods.
Intervention uptake
Among 278 patients in the ST period, 179 (64%) were skin test eligible. Of 43 (24%) patients skin tested, none was allergic (Fig 2) . There were 2802 Web page views in the APP period, with 292 unique page views lasting 26 seconds on average (see Table  E2 in this article's Online Repository at www.jacionline.org). There were 112 unique users who completed decision support.
Primary outcome, inpatient penicillin or cephalosporin use
Of 148 patients in the SOC period, 56 (38%) were treated with a penicillin or cephalosporin (Table II) . Of 278 patients in the ST period, 116 (42%) were treated with a penicillin or cephalosporin antibiotic. Of 43 ST-PP patients, 31 (72%) patients were treated with a penicillin or cephalosporin antibiotic. Of 199 patients in the APP period, 99 (50%) were treated with a penicillin or cephalosporin antibiotic; treated patients received the penicillins and/or cephalosporins after negative skin testing (n 5 5 [5%]) or directly with a test dose or full-dose challenge (n 5 94 [95%]).
In univariable analyses compared to SOC, penicillin or cephalosporin use was similar in the ST period overall (P 5 .44), but greater in the ST-PP analysis (P < .001) and overall in the APP period (P 5 .03). In the multivariable logistic regression model, patients in the ST period did not have significant increased odds of receiving a penicillin or (2) reported penicillin allergy, and (3) prescribed 1 or more antibiotic doses. From this cohort, we excluded readmissions and patients whose admission was not for treatment of an infection. Of 625 patients meeting these criteria, 148 were admitted in the SOC period, 278 were admitted in the ST period, and 199 were admitted in the computerized guideline period.
cephalosporin (adjusted OR, 1.3; 95% CI, 0.8-2.0; Table III) . ST-PP patients had increased odds of receiving a penicillin or cephalosporin, with an adjusted OR of 5.7 (95% CI, 2.6-12.5). APP period patients had increased odds of receiving a penicillin or cephalosporin, with an adjusted OR of 1.8 (95% CI, 1.1-2.9).
Secondary outcomes
Although a similar proportion of patients in the ST period used a penicillin or cephalosporin on discharge compared with the SOC period, a greater frequency of ST-PP patients received a penicillin or cephalosporin on discharge compared with the SOC period (26% vs 16%; P 5 .18; Table II ). In the multivariable model, there were increased odds of a penicillin or cephalosporin used for discharge treatment for ST-PP patients, compared with the SOC period (OR, 2.5; 95% CI, 1.04-6.2; Table III ). In both univariable and multivariable analyses, the frequency of discharge use of a penicillin or cephalosporin was similar in the APP period, compared with the SOC period (Tables II and III) .
The overall frequency of alternative antibiotic use was largely similar across periods (Tables II and III, bottom) .
There were no adverse drug reactions identified in the SOC period or the ST period. One patient in the APP period with a history of penicillin allergy developed erythema and pruritus to amoxicillin after a negative penicillin skin test result.
Balance measure
The frequency of inpatient macrolide antibiotic use was unchanged by the interventions, compared with SOC (10%), for all comparisons (ST, 10%; P 5 .89; ST-PP, 2%, P 5 .10; APP, 12%; P 5 .67).
DISCUSSION
In this study of 2 antibiotic stewardship innovations designed to safely increase the use of favorable beta-lactam antibiotics in medical inpatients reporting penicillin allergy, we found that the allergy history-driven computerized guideline as well as completed skin testing significantly increased penicillin or cephalosporin antibiotic use. Although ST period patients did not have increased odds of penicillin or cephalosporin use, patients in the computerized guideline period had a significant almost 2-fold increased odds of receiving a penicillin or cephalosporin antibiotic. Completed skin testing, in the perprotocol analysis, had an almost 6-fold increased odds of receiving a penicillin or cephalosporin antibiotic. Among inpatients treated for infections, 5% to 25% report an allergy to penicillin. 1, 4, 7, 16, 31 Although up to 3 in 4 patients with alleged penicillin allergy warrant inpatient treatment with a betalactam antibiotic, 4 only half were receiving these antibiotics in the baseline SOC period. We implemented interventions that were associated with increased use of favorable penicillins and cephalosporins, reflecting improved antibiotic choice and stewardship. Because the impact of overreporting penicillin allergy is felt beyond antibiotic utilization to resultant readmissions, 31 treatment failures, 8 and adverse events, 4 safely increasing the use of penicillin and cephalosporin antibiotics in this patient population is a crucial first step toward improved quality of care and reduced cost. 32 We did not observe a significant impact of the interventions on the frequency of discharge use of penicillins or cephalosporins in the primary analyses, or inpatient use of alternative antibiotics. The former may be explained by providers' choice for outpatient therapy placing more emphasis on medication convenience. Yet, we observed that patients who completed skin testing in the per-protocol analysis had increased odds of penicillin or cephalosporin use at discharge, which may indicate that skin test negative patients have improved antibiotic use beyond their hospitalization. It was not surprising that neither intervention had a significant impact on the use of alternative antibiotics, because medical inpatients with infections are often given empiric treatment that includes the alternative antibiotics. Previous studies addressing overreported penicillin allergies have demonstrated the utility of skin testing in emergency, intensive care, and perioperative patients. 10, 13, 33 Fewer skin testing studies are reported among highly selected inpatient subsets. 16, [34] [35] [36] Alternative approaches to address inpatient penicillin allergies have included consultation by allergy specialists 34, 37 and guidelines/clinical pathways. 26, 38 By implementing and assessing both a skin testing approach and guideline approach in sequential cohorts at the same institution, we were able to determine the overall hospital policy level impact of these interventions.
Although completed skin testing was effective at improving inpatient antibiotic choice, 36% of patients were ineligible for testing, consistent with previous estimates that deemed 4% to 59% of inpatients skin test ineligible. 16, 39, 40 One modifiable reason that patients in the ST period overall may not have experienced a significant increase in penicillin and cephalosporin use was an inability to coordinate testing for 58 skin test eligible patients. However, we skin tested 16% of all patients reporting penicillin allergy on antibiotics in this period, and 24% of those who were skin test eligible, largely comparable to the 19% yield achieved through the use of a designated pharmacist performing skin testing in a previous study. 36 Still, more patients would have had testing completed, and overall findings may have differed, had we hired an onsite skin testing clinician.
Despite the challenges associated with coincidental innovation at the time of electronic health record conversion, [41] [42] [43] [44] there were almost 300 unique Web page views of the computerized guideline, and 112 providers completed decision support. Given the computerized guideline's overall positive impact on antibiotic use, reliance on new technology over new human capital, and relative ease of implementation, the computerized guideline and decision support tool have great potential to improve the care of inpatients with reported penicillin allergy. This conclusion is further strengthened by our knowledge of the intervention's limited electronic health record integration and basic user interface during the study period. 45, 46 Furthermore, the computerized guideline and decision support tool can provide guidance when hospitals do not have access to allergists or skin testing, or when patients are otherwise ineligible or unwilling to complete a skin test.
Innovations in health care delivery substantially change care, whereas quality improvement targets incremental change. 47 The interventions implemented challenged the status quo by introducing a new process (ie, skin testing) and a new technology (ie, computerized guideline) to change the care of inpatients labeled penicillin-allergic. Health care systems are ill-equipped to address penicillin allergy because general clinicians have poor drug allergy knowledge, 25 there are inadequate numbers of allergy specialists to perform these evaluations, 48, 49 and less than 15% of US hospitals have the skin testing reagent on formulary. 50 Thus, health care delivery innovations are needed with investments in infrastructure, technology, and/or human resources. These investments may contain elements of the computerized guideline, which was easy to implement and relatively inexpensive. Hospitals will likely need processes for performing skin testing and test dose challenges, even without access to allergy specialists.
Although the hospital policy perspective of this study afforded us a realistic view of the overall impact of our interventions, the analysis underestimates the potential impact because of incomplete uptake. Using a per-protocol analysis for the ST period provided additional insight, but is subject to selection bias toward patients who would most clearly benefit from the penicillin skin test. Although a per-protocol analysis may have been similarly favorable for patients whose providers used the computerized guideline, these data were not available. Although cohorts were identified prospectively, data were gathered retrospectively, potentially resulting in missing or misclassification information; for example, we could not identify mild adverse reactions if they were not included in the electronic health record. Data were also gathered in 2 different electronic health record systems; however, variables were collected by medicine-trained chart verifiers comfortable with both systems. We acknowledge that our quasi-experimental design limits our ability to demonstrate causality, but we included the macrolide balance measure to provide reassurance against unmeasured confounders or secular trends. This study assessed antibiotic outcomes within patients' *Data presented as OR (95% CI). Adjusts for frequency of methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus colonization, an infection as the admission diagnosis, length of stay, concomitant cephalosporin allergy, and penicillin intolerance. àAdjusts for frequency of methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus colonization, an infection as the admission diagnosis, length of stay, concomitant cephalosporin allergy, penicillin intolerance, and Allergy/Immunology consultation. §P < .001. kP 5 .03. {P 5 .02. #P 5 .04.
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 1 incident admission only, and did not capture important longitudinal outcomes, such as clarity of allergy status/documentation or types of antibiotics (ie, beta-lactams or alternatives) used after discharge or in future hospitalizations. Finally, internal medicine patients may not be similar to other types of inpatients (eg, surgical and obstetric), and results may differ in hospitals whose patients, resources, and/or personnel differ from those of the BWH.
In summary, we implemented and assessed 2 interventions in the care of hospitalized medical patients with reported penicillin allergy. Although barriers to completing skin testing routinely in medical patients made skin testing impractical and without an overall impact on antibiotic use, skin tested patients had almost 6-fold odds of increased penicillin and cephalosporin use. The computerized guideline had an overall positive, almost 2-fold impact, with a feasible implementation and long-term strategy for greater technology integration. Clinical implications: Improved antibiotic choice among medical inpatients reporting previous penicillin allergy was achieved using a computerized guideline, which resulted in overall significant increased odds of penicillin or cephalosporin use compared with SOC (adjusted OR, 1.8; 95% CI, 1.1-2.9).
METHODS
Standard procedure for skin testing and test doses in all periods
Skin testing was performed using Pre-Pen (ALK-Abello) and dilutions of penicillin G (10,000 units/mL for epicutaneous and intradermal testing). Penicillin mixing and dilutions were performed by the central inpatient pharmacy. Before skin testing, written informed consent was obtained from the patient, or a designated health care proxy. All skin testing was performed by an Allergy/Immunology physician, registered nurse, or nurse practitioner. All negative penicillin skin test results were followed with a single oral observed challenge dose (ie, test dose) of amoxicillin 250 mg. Although not an adult therapeutic dose, amoxicillin 250 mg is adequate for provoking an IgE-mediated reaction and is the standard protocol used by BWH Allergy/Immunology.
Computerized guideline-recommended test doses to beta-lactam antibiotics without preceding skin testing followed a 2-step protocol. E1 Guided by our previous studies, E1,E2 the initial dose was one-tenth of an intravenous antibiotic dose or one-fourth of an oral antibiotic dose. The second dose, administered 30 minutes later, comprised the remaining part of the therapeutic dose (ie, nine-tenth of the intravenous dose or three-fourth of the oral dose). All test doses were given on the general medical floor, during weekday, daytime hours with one-to-one nursing for the duration of the procedure. Nurses assessed patients every 30 minutes for the duration of the challenge (ie, 90 minutes). Guideline-recommended full-dose challenges to beta-lactam antibiotics without preceding skin testing were ordered regularly, without any specific administration or observation instructions.
Evidence supporting the structure of the clinical pathway/guideline Evidence supportive of the clinical guideline structure has been previously described. E2 The guideline uses the hypersensitivity reaction type E3 to inform which drugs should be avoided, which can be used initiating with a test dose, and which can be initiated with a full dose. Providers assign the patient's reaction into 1 of 3 reaction categories that have corresponding risk stratification: (1) type II to IV reaction, (2) type I reaction, or (3) mild reaction ( Fig E3) . Guideline implementation was previously associated with increased test dose challenges of beta-lactam antibiotics and improved first-line antibiotic therapy in methicillin-sensitive Staphylococcus aureus bacteremia.
E2,E4-E7
Development and testing of computerized guideline/app
The previously studied guideline was adapted into a mobile-friendly intranet site maintained behind the Partners HealthCare firewall. The clinical decision support functionality of the Web site was developed by an allergist/ immunologist and quality and safety leader (K.G.B., Fig E2) , and revised on the basis of input from allergists, infectious diseases experts, and pharmacists in Partners HealthCare System. In addition to housing links to the PDF versions of the pathway, the Web site included links to educational videos (offered through Vidscript services E8 ) and national data supporting penicillin allergy evaluation. Computerized guideline users could access the pathway figures directly if they were comfortable with allergy history taking, or they could complete clinical decision support to aid in the allergy history taking.
Before implementation, the clinical decision support functionality of the app was tested by 16 providers from across Partners HealthCare, and subsequently revised on the basis of cumulative feedback, though limitations on speed, design/user experience, and electronic health record integration persisted.
With the start of the computerized guideline period, laminated pocket cards and posters with pathway figures and Web site instructions were delivered to internal medicine floors for clinical providers (Fig E3) .
Determination of innovation period length and statistical power
For 80% power to detect an increase of 15% in the use of penicillin or cephalosporin antibiotics, we required 750 total inpatients (SOC, 150; ST, 300; computerized guideline, 300), with 30% penicillin or cephalosporin use expected in the SOC period using 2.5% alpha. With approximately 60 patients per month meeting the electronic trigger criteria, we anticipated intervention period lengths of 3 to 5 months in duration. Given anticipated exclusions for readmissions and patients not treated for a presumptive infection, we terminated enrollment when we reached a cohort of 1000 medicine inpatients. 
FIG E2.
Example clinical decision support offered by the computerized guideline application. The computerized guideline application contained optional clinical decision support for taking a drug allergy history. After answering questions from the patient's allergy history, the decision support would group immunologic reactions into 1 of 3 reaction categories from the penicillin hypersensitivity pathway. In this example, the patient's allergy history was suspicious for a serum-sickness like reaction to penicillin, a type III hypersensitivity reaction.
FIG E3.
Disseminated posters and pocket cards in the computerized guideline application period. Educational posters were hung in workrooms, emailed to clinicians, and dispensed as laminated pocket cards. One poster focused on accessing and using the computerized guideline application while the other displayed the penicillin hypersensitivity pathway. 
